Limits...
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW - Atten Defic Hyperact Disord (2009)

Bottom Line: All the groups demonstrated improvement on the SNAP-IV ODD and ADHD-combined subscales (P<.001).Symptom improvement was numerically greater in the non-remitter (2.4 mg/kg/day compared with the non-remitter 1.2 mg/kg/day) group.However, a higher atomoxetine dose may benefit some patients.

View Article: PubMed Central - PubMed

Affiliation: Discipline of Psychological Medicine, Concord Clinical School, University of Sydney, Sydney, Australia.

Show MeSH

Related in: MedlinePlus

Clinical global impression––improvement ADHD/ODD visitwise scores by Study Period III ODD remitter groups. aP-value comparison non-remitter atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day, bP-value comparison non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day; *P < .05; **P < .01; ***P < .001
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2837233&req=5

Fig3: Clinical global impression––improvement ADHD/ODD visitwise scores by Study Period III ODD remitter groups. aP-value comparison non-remitter atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day, bP-value comparison non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day; *P < .05; **P < .01; ***P < .001

Mentions: As seen in Fig. 3, at every visit from Weeks 2 to 12 there was a significantly greater improvement on the CGI-I ADHD/ODD score in the remitter 1.2 mg/kg/day group compared with the non-remitter 2.4 mg/kg/day group or the non-remitter 1.2 mg/kg/day group. From Weeks 2 to 12, there were no significant differences in the CGI-I ADHD/ODD score between the non-remitter groups.Fig. 3


Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW - Atten Defic Hyperact Disord (2009)

Clinical global impression––improvement ADHD/ODD visitwise scores by Study Period III ODD remitter groups. aP-value comparison non-remitter atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day, bP-value comparison non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day; *P < .05; **P < .01; ***P < .001
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2837233&req=5

Fig3: Clinical global impression––improvement ADHD/ODD visitwise scores by Study Period III ODD remitter groups. aP-value comparison non-remitter atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day, bP-value comparison non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day; *P < .05; **P < .01; ***P < .001
Mentions: As seen in Fig. 3, at every visit from Weeks 2 to 12 there was a significantly greater improvement on the CGI-I ADHD/ODD score in the remitter 1.2 mg/kg/day group compared with the non-remitter 2.4 mg/kg/day group or the non-remitter 1.2 mg/kg/day group. From Weeks 2 to 12, there were no significant differences in the CGI-I ADHD/ODD score between the non-remitter groups.Fig. 3

Bottom Line: All the groups demonstrated improvement on the SNAP-IV ODD and ADHD-combined subscales (P<.001).Symptom improvement was numerically greater in the non-remitter (2.4 mg/kg/day compared with the non-remitter 1.2 mg/kg/day) group.However, a higher atomoxetine dose may benefit some patients.

View Article: PubMed Central - PubMed

Affiliation: Discipline of Psychological Medicine, Concord Clinical School, University of Sydney, Sydney, Australia.

Show MeSH
Related in: MedlinePlus